The reduction in price target may have a neutral to slightly negative short term impact on Leap Therapeutics' stock price as it suggests a lower valuation than previously estimated. However, maintaining the Outperform rating indicates a continued positive outlook on the company's performance, which could balance out the negative impact of the price target cut.